Synthesis of novel internal standards for the quantitative determination of plasma ceramide trihexoside in Fabry disease by tandem mass spectrometry  by Mills, Kevin et al.
Synthesis of novel internal standards for the quantitative determination
of plasma ceramide trihexoside in Fabry disease by
tandem mass spectrometry
Kevin Mills, Andrew Johnson, Bryan Winchester
Biochemistry, Endocrinology and Metabolism Unit, Institute of Child Health (University College London), 30 Guilford Street,
London WC1N 1EH, UK
Received 16 January 2002; revised 18 February 2002; accepted 19 February 2002
First published online 27 February 2002
Edited by Guido Tettamanti
Abstract The concentration of globotriaosylceramide (ceramide
trihexoside (CTH)) in the plasma of patients with Fabry disease
has been determined quantitatively by tandem mass spectrometry
(MS) using novel internal standards, [D4]C-16 CTH and C-17
CTH, which were synthesised enzymically from lyso-CTH using
the reverse reaction of sphingolipid ceramide N-deacylase. C-17
CTH was also synthesised chemically from lyso-CTH. This
strategy has also been used to prepare standards for the
quantitative determination by MS of other glycosphingolip-
ids. ß 2002 Federation of European Biochemical Societies.
Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Fabry disease is an X-linked lysosomal storage disease re-
sulting from a de¢ciency of the lysosomal hydrolase, K-galac-
tosidase A (EC 3.2.1.22), which leads to the progressive accu-
mulation within lysosomes of glycosphingolipids with
terminal K-galactosyl residues [1]. A¡ected hemizygous males
develop various symptoms in childhood or early adolescence,
including severe pain and paresthesias in the extremities, an-
giokeratoma and corneal opacities, and death usually occurs
in the ¢fth decade from renal failure or cardiac disease. Atyp-
ical clinical variants with some residual activity may be
asymptomatic or mildly a¡ected with late onset and mainly
cardiac manifestations. Heterozygous females either su¡er
from a milder form of the disease, or may be asymptomatic,
but occasionally they may be as severely a¡ected as the hemi-
zygous males [2]. The major storage product is ceramide tri-
hexoside (CTH) or globotriaosylceramide (GbOse3Cer, Gb3,
GL-3) [1]. Galabiosylceramide is also found in certain tissues
as are blood group B substances in patients with blood group
B or AB [3]. Storage occurs predominantly in the endothelial,
perithelial and smooth muscle cells of blood vessels but there
is deposition in many other cell types and storage products are
present in body £uids. The level of globotriaosylceramide in
tissues, plasma or urine can be used to follow the course of
the disease or conversely to monitor treatment [4,5]. Several
methods (for reviews see [1,6]) have been used to measure
globotriaosylceramide directly including thin-layer chroma-
tography (TLC) [7], enzyme-linked immunosorbent assay
(ELISA) [6] and mass spectrometry (MS) [8], or indirectly
by release and measurement of the oligosaccharide moiety
by GLC [9] or high-performance liquid chromatography
[10]. Glycosphingolipids can be detected and identi¢ed readily
by tandem MS (MS/MS) [11,12] but their quantitative deter-
mination has been handicapped by the lack of suitable inter-
nal standards [13,14]. In this paper we describe the synthesis
and use of novel internal standards for the quantitative deter-
mination of globotriaosylceramide and other glycolipids in
plasma using MS/MS.
2. Materials and methods
2.1. Materials
Plasma was obtained from male patients with the classic form of
Fabry disease and from normal controls with informed consent. Hu-
man erythrocyte CTH (GalK-(1C4)GalL-(1C4)Glc-ceramide) (glo-
botriaosylceramide, GbOse3Cer, Gb3, GL-3 or CTH) was obtained
from Sigma (Dorset, UK). Lyso-CTH (GalK-(1C4)GalL-(1C4)Glc-
sphingosine) and sphingolipid ceramide N-deacylase were obtained
from Calbiochem, CA, USA. [D4]-palmitic acid labelled in the
7,7,8,8 positions was supplied by Cambridge Isotopes, MA, USA.
All chemical reagents were of analytical grade from Sigma, Dorset,
UK.
2.2. Chemical synthesis of C-17 CTH
50 Wg of lyso-CTH was dried completely under N2 in a glass vial
and then dissolved in 100 Wl of heptadecanoic anhydride in chloro-
form (10 mg/ml). Pyridine (300 Wl) was added and the solution was
vortexed thoroughly and left at room temperature for 30 min. After
drying completely under nitrogen to remove all the excess pyridine,
100 Wl of heptadecanoic anhydride in chloroform (100 mg/ml) and 300
Wl of pyridine were added to the reaction mixture, which was again
thoroughly mixed and left at room temperature for 30 min. The re-
action mixture was dried under nitrogen and desalted using a C-18
solid-phase extraction cartridge (LiChrolute, Merck, Poole, Dorset,
UK) [6].
2.3. Enzymic synthesis of C-17 CTH and [D4]C-16 CTH
50 Wg (V50 nmol) of human erythrocyte CTH was incubated in 20
Wl of sodium acetate bu¡er, pH 5.0 with 1 mU of sphingolipid cer-
amide N-deacylase for 16 h at 37‡C essentially as described by Ito et
al. [15]) except that Triton X-100 was replaced by fatty acid-free
bovine serum albumin (BSA) (1%, w/v). The reaction mixture was
freeze-dried and the lipid products were extracted in 5 Wl of chloro-
form:methanol (1:2, v/v). The extent of the enzymatic deacylation
was determined by TLC on silica gel plates (Silica Gel 60, Merck,
Poole, Dorset, UK) using chloroform:methanol:acetic acid (10%)
(5:4:1) as the mobile phase. The glycosphingolipids and lyso-glyco-
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sphingolipids were detected using iodine vapour and identi¢ed by
comparison with standards. Lyso-CTH was scraped o¡ the TLC plate
and recovered from the silica using two washes of 500 Wl of chloro-
form:methanol (2:1, v/v).
The reverse reaction of sphingolipid ceramide N-deacylase [16] was
exploited to reacylate lyso-CTH to form [D4]C-16 CTH, a type 1
internal standard (an isotopically labelled analogue, which is chemi-
cally identical to but with a higher mass than the target analyte), and
C-17 CTH, a type 2 internal standard (a structurally related com-
pound with similar chemical characteristics to the analyte) for quan-
titation of CTH by MS. Puri¢ed or commercial lyso-CTH (75 nmol)
was incubated with 75 nmol of heptadecanoic acid or [D4]-palmitic
acid and 200 WU of sphingolipid ceramide N-deacylase in 20 Wl of 25
mM sodium phosphate bu¡er, pH 6.5 (containing fatty acid-free BSA
(1%, w/v)), for 20 h at 37‡C. The products of the reacylation reaction
were analysed using TLC as described above. Over 90% conversion of
lyso-CTH to CTH was achieved. For larger-scale preparation of the
internal standards, the reaction products were desalted using a C-18
solid-phase extraction cartridge (LiChrolute, Merck, Poole, Dorset,
UK). The C-18 cartridge was ¢rst primed with 5 ml of methanol,
followed by 5 ml of H2O. The reaction mixture was added directly
to the cartridge and the salts and residual detergent present in the
enzyme preparation were removed by successive washing with 3 ml
H2O, 3 ml of 60% methanol and 3 ml of 70% methanol. The CTH
internal standards were eluted from the column using 2 ml of meth-
anol followed by 2 ml chloroform:methanol (2:1, v/v).
2.4. Measurement of CTH in plasma
1 Wg of CTH internal standard was added to 100 Wl of plasma, from
which the total lipid was extracted by the addition of 2 ml of chlor-
oform:methanol (2:1, v/v) with shaking on a multivortexer for 20
min. Precipitated protein was removed by centrifugation at 3000Ug
for 10 min. The chloroform:methanol (2:1, v/v) layer was transferred
to a vial and 400 Wl of H2O was added and the vial was shaken for a
further 20 min. The two layers were separated by centrifugation for 10
min at 3000Ug and the lower layer containing the neutral glycolipids
including the CTH was transferred to a new vial and dried under N2.
The CTH was desalted prior to MS by reconstitution in chloroform
followed by solid-phase extraction on a C-18 column (LiChrolute,
Merck, Poole, Dorset, UK) with elution with acetone:methanol
(9:1) [6].
2.5. Electrospray ionisation^MS/MS (ESI^MS/MS)
MS of glycolipids was carried out using a triple quadrupole VG
Quattro I instrument (MicroMass, Altrincham, UK). The instrument
was operated in positive ionisation mode. Samples were directly in-
fused into the electrospray source via a 25 mm (i.d.) fused silica trans-
fer line by means of a Harvard syringe pump at a £ow rate of 25 Wl/
min. The capillary voltage was maintained at 3.43 kV with a cone
voltage of 173 V. The source temperature was held constant at 80‡C
and nitrogen was used as the nebulising gas at a £ow rate of 30 l/h.
The masses of all the CTH isoforms were determined by operating the
mass spectrometer in scan mode over a mass range of m/z 700^1300.
Product ions were determined over a mass range of m/z 50^1200
following collision-induced dissociation using argon as the collision
gas. The optimum collision energy was determined to be 70 eV with
an optimum gas cell pressure of 3.2U1033 mbar. Data were acquired
using neutral loss scanning of m/z 162.0, operating in multiple channel
acquisition mode and with a dwell time for each ion species of 100 ms.
For quantitative analyses samples were infused into the mass spec-
trometer using the electrospray ion source and CMA/200 refrigerated
auto sampler.
2.6. Liquid secondary ionisation^MS/MS (LSI^MS/MS)
To con¢rm the structures of the individual CTH isoforms and the
internal standard, the CTH isoforms were analysed using the tandem
Fig. 1. ESI^MS spectra of (a) lyso-CTH, (b) C-17 CTH, (c) [D4]C-16 CTH and (d) CTH standard from human erythrocytes.
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Fig. 2. LSI^MS/MS daughter ion spectra of (a) C-16 CTH and (b) C-17 CTH.
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mass spectrometer operating with an LSI source (LSI^MS/MS). This
ionisation mode produced more extensive fragmentation through the
ceramide backbone of the CTH, which could not be achieved using
the ESI source, and allowed de¢nitive determination of the acyl group
in each CTH isoform. LSI^MS/MS of glycolipids was carried out
using a triple quadrupole VG Quattro I instrument (MicroMass, Al-
trincham, UK). The instrument was ¢tted with an LSIMS source
(CsI) operating with an accelerating voltage of 9 kV in positive ion-
isation mode. MS/MS experiments were conducted using a collision
energy of 30 eV and a gas cell pressure of 3.2U1033 mbar (argon).
3. Results
3.1. Chemical synthesis of C-17 CTH and enzymic synthesis of
C-17 CTH and [D4]C-16 CTH
The ESI^MS spectrum for lyso-CTH consisted predomi-
nantly of an ion of 809.0 m/z, which corresponds to a
mono-sodiated GalK-(1C4)GalL-(1C4)Glc-sphingosine (d-
18) (Fig. 1a). The ESI^MS spectrum for the product of the
chemical acylation of lyso-CTH had a molecular ion of 1060.9
m/z, consistent with the formation of C-17 CTH (CTH d-18:1
C-17) (Fig. 1b). The structure of the C-17 CTH was con¢rmed
by LSI^MS/MS (Fig. 2b). The fragmentation pattern con-
tained ions of 1039.3 m/z, 534.3 m/z and 264.0 m/z corre-
sponding to the molecular ion and the daughter ions for the
ceramide Cer (d-18:1 C-17^1H2O) and sphingosine (d-18:1)
moieties, respectively.
As the yield for the chemical synthesis of C-17 CTH was
less than 10%, the speci¢city of enzymes was exploited to
make C-17 CTH. Firstly, lyso-CTH was prepared from the
commercially available erythrocyte CTH by using sphingoli-
pid ceramide N-deacylase [14]. Lyso-CTH was puri¢ed from
the reaction mixture by TLC and its structure established by a
combination of ESI^MS/MS and LSI^MS/MS. C-17 CTH
was synthesised enzymically from lyso-CTH, which had been
prepared enzymically or commercially, using the reverse reac-
tion of sphingolipid ceramide N-deacylase [15]. The C-17
CTH was puri¢ed from the enzymic reaction mixture as de-
scribed above and analysed by ESI^MS/MS. The product ion
spectrum was identical to that obtained for the chemically
synthesised compound (Fig. 1b) and its structure was con-
¢rmed by LSI^MS/MS as for the chemically synthesised mol-
ecule (Fig. 2b). The yield for the enzymic acylation reaction
was s 90% as determined by the ratio of the lyso-CTH to
Fig. 3. ESI^MS/MS spectra of CTH in (a) control and (b) Fabry plasma obtained by neutral loss scanning of 162.0 m/z.
Fig. 4. Total plasma CTH (Wg/ml) in control and Fabry patient
plasma measured using two internal standards.
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CTH after TLC. Therefore it was possible to make the C-17
CTH enzymically in very high yields (s 90%) either directly
from commercially available lyso-CTH or from human CTH
by a two-step enzymic process. [D4]C-16 CTH was synthe-
sised enzymically by substituting [D4]-palmitic acid for the
heptadecanoic acid in the second step of the enzymic proce-
dure, with a comparable yield. The structure of the [D4]C-16
CTH was con¢rmed by a combination of ESI^MS/MS (Fig.
1c) and LSI^MS/MS as for the C-17 CTH.
3.2. Calibration of C-17 CTH and [D4]C-16 CTH with
authentic human erythrocyte CTH
Authentic human erythrocyte CTH consists of a mixture of
isoforms with acyl chains of di¡erent masses (Fig. 1d). The
most abundant forms contain lignoceric acid (C24:0) and
nervonic acid (C24:1) with appreciable amounts of their hy-
droxylated derivatives. Other constituents are the C24:2 acid,
behenic acid (C22:0) and its mono-unsaturated derivative
(C22:1) and palmitic acid (C16:0) isoforms. All of the ions
in the spectrum could be attributed to mono-sodiated CTH
isoforms. The masses of the ions suggested that the sphingo-
sine moiety is d-18:1, which was con¢rmed by LSI^MS/MS
(Fig. 2a), which showed a characteristic fragmentation ion of
264 m/z corresponding to sphingosine d-18:1 minus 2. H2O
[11]. C-17 CTH and [D4]C-16 CTH were calibrated by mixing
constant amounts with di¡erent amounts of the authentic
CTH standard and analysing the mixtures by ESI^MS/MS.
A linear relationship between the ratio of the responses for
the standards and each molecular species of CTH was ob-
tained, permitting construction of calibration curves.
3.3. Measurement of CTH in plasma from normal controls and
patients with Fabry disease
The total CTH in a single normal plasma was measured in
replicate using C-17 CTH (n = 12) or [D4]C-16 CTH (n = 11)
as the internal standard with coe⁄cients of variation of 9.9%
and 7.9%, respectively. C-16 CTH was the major form of
CTH in both normal and Fabry plasma but all the forms of
CTH are elevated in the plasma from a male patient with
classic Fabry disease (Fig. 3). The levels of the total CTH
and of the individual isoforms were measured quantitatively
by neutral loss scanning of m/z 162.0, operating in multiple
channel acquisition mode and using C-17 CTH and [D4]C-16
CTH as the internal standards (Fig. 4). The mean levels of
total CTH in the normal plasma were 8.4 þ 1.8 Wg/ml (range
4.5^10.7, n = 38) and 8.5 þ 1.3 Wg/ml (range 6.0^10.3, n = 15),
respectively, and in the Fabry plasma 29.1 þ 9.9 Wg/ml (range
15.8^44.5, n = 13) and 21.4 þ 5.8 (range 13.5^33.1, n = 13), re-
spectively.
4. Discussion
The quantitative measurement of glycosphingolipids by
MS/MS requires appropriate internal standards. The enzymic
synthesis of a type 1 internal standard, i.e. [D4]C-16 CTH,
and the enzymic or chemical synthesis of a type 2 internal
standard, i.e. C-17 CTH, for the measurement of CTH are
described in this paper. The yield for the chemical synthesis of
C-17 CTH from lyso-CTH was very low but exploitation of
the reverse reaction of sphingolipid ceramide N-deacylase to
reacylate lyso-CTH gave very good yields. Furthermore, the
hydrolase activity of ceramide N-deacylase can be used to
deacylate CTH to prepare the lyso-CTH, which can then be
reacylated enzymically or chemically to produce a type 1 or
type 2 internal standard.
Using the novel internal standards, the levels of CTH were
measured by MS/MS in plasma from patients with the classic
form of Fabry disease and from normal control individuals.
An approximately four-fold increase in total CTH was found
in the plasma from Fabry patients. The predominant isoform
of CTH in both normal and Fabry disease plasma is C-16
CTH whereas the predominant forms in human erythrocytes
have C24:0 and C24:1 acyl groups. The ratio of C-16 CTH to
C24:0 CTH only increased slightly from V0.3 in normal
plasma to V0.4 in the Fabry plasma, suggesting that the
majority of the circulating storage product is not derived di-
rectly from senescent erythrocytes. Higher levels of total
CTH, particularly in normal controls, were observed with
our method than by ELISA [6] and GLC [9] (12.6 þ 3.7 and
7.6 þ 2.1 Wg/ml, respectively, for Fabry plasma and 0.9 þ 0.4
and 2.1 þ 0.7 Wg/ml, respectively, for normal plasma). How-
ever the levels of C-16 CTH alone, measured with C-17 CTH
and [D4]C-16 CTH, 4.1 þ 1.1 Wg/ml (range 2.6^6.1, n = 38) and
2.4 þ 0.3 Wg/ml (range 2.0^3.0, n = 15), respectively, for normal
plasma, and 12.4 þ 3.4 Wg/ml (range 7.5^17.4, n = 13) and
8.4 þ 3.2 Wg/ml (range 4.7^15.2, n = 13), respectively, were
comparable.
In principle the strategy of preparation of the lyso-com-
pound followed by reacylation to synthesise an internal stan-
dard can be applied to any glycosphingolipid that is a sub-
strate for the ceramide N-deacylase. We have prepared C-17,
C-19, C-21, C-23 and C-25 CTH, chemically and enzymically,
as standards for measuring the di¡erent forms of CTH found
in di¡erent tissues. We have also prepared C-17-GM1-ganglio-
side, -GM2-ganglioside and -GM3-ganglioside and [D4]C-16-
galactocerebroside, -galactocerebroside-3-sulphate, lactosyl-
ceramide and -globoside as internal standards for measuring
the storage products in tissues and organs from other glyco-
sphingolipidoses by MS/MS (manuscript in preparation).
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